Increase in minimal erythemal dose following oral administration of an antioxidant complex based on a mix of carotenoids: Double-blind, placebo-controlled trial

2017 ◽  
Vol 33 (5) ◽  
pp. 284-286 ◽  
Author(s):  
Jose-Manuel Carrascosa ◽  
Nuria Floriach ◽  
Elisabet Sala ◽  
Jose Aguilera
Keyword(s):  
Oral Administration ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Minimal Erythemal Dose

scholarly journals Infantile Colic Treated With Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8330: A Randomized, Double-Blind, Placebo-Controlled Trial

2021 ◽  
Vol 9 ◽  
Author(s):  
Ke Chen ◽  
Changqi Liu ◽  
Hua Li ◽  
Yuehua Lei ◽  
Chenggui Zeng ◽  
...  
Keyword(s):  
Oral Administration ◽  
Controlled Trial ◽  
Bifidobacterium Longum ◽  
Intervention Group ◽  
Infantile Colic ◽  
Double Blind ◽  
Pediococcus Pentosaceus ◽  
Double Blind Placebo ◽  
Colony Forming Units

Background: Colic is a common condition in infants <4 months of age. Attempts to treat infantile colic with probiotics have shown variable efficacy and overall low evidence of success. In this work, we tested the hypothesis that oral administration of Bifidobacterium longum CECT7894 (KABP042) and Pediococcus pentosaceus CECT8330 (KABP041) mix (1 × 109 colony forming units) would improve the symptoms of infantile colic.Methods: A total of 112 exclusively breastfed or mixed fed infants aged <2 months and meeting the ROME IV criteria for infantile colic were recruited. The infants were randomized in a double-blind, placebo-controlled trial to receive orally administered probiotics (intervention group, IG, n = 48) or placebo (placebo group, PG, n = 42) daily for 21 days.Results: Infants in the IG had significantly shorter crying time (p < 0.001) on day 7 [IG vs. PG, median (25−75th percentile): 38 (3.5–40.5) vs. 62 (40–108) min/day], day 14 [IG vs. PG: 20 (0–40) vs. 50 (30–75) min/day], and day 21 [IG vs. PG: 14 (0–33) vs. 40 (28–62) min/day]. Higher responder ratio and fewer crying/fussing episodes on days 7, 14, and 21 and better stool consistency on day 21 were observed in the IG (p < 0.01) as compared to the PG. Conversely, no significant effects on stool frequency or quality of life were observed.Conclusions: In summary, daily oral administration of B. longum CECT7894 (KABP042) and P. pentosaceus CECT8330 (KABP041) was an effective treatment for shortening crying time due to infantile colic and for improving fecal consistency. This trial was registered retrospectively in December 2019 with a trial number of ISRCTN92431452.

Oral Pilocarpine for Treatment of Opioid-induced Oral Dryness in Healthy Adults

2004 ◽  
Vol 83 (5) ◽  
pp. 393-397 ◽  
Author(s):  
B. Götrick ◽  
S. Åkerman ◽  
D. Ericson ◽  
R. Torstenson ◽  
G. Tobin
Keyword(s):  
Oral Administration ◽  
Controlled Trial ◽  
The State ◽  
Healthy Adults ◽  
Drug Induced ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Before And After ◽  
Oral Dryness ◽  
Baseline Characteristics

Pilocarpine induces a profuse flow of saliva when administered orally, but effects on drug-induced oral dryness have not been examined. The aim of this trial was to investigate if pilocarpine increases production of saliva in individuals suffering from dry mouth due to treatment with opioids. Sixty-five individuals were enrolled in a randomized, double-blind, placebo-controlled trial. The subjects received tramadol (50 mg t.d.s.) to induce oral dryness, and were thereafter assigned to one of three groups. Secretion rate of saliva was measured before and after tramadol, and after the oral administration of pilocarpine (5 mg), placebo, or no treatment. Baseline characteristics did not differ among the groups (mean ± SEM: 0.37 ± 0.06 mL/min), and tramadol lowered the secretion at the same level in all groups (0.15 ± 0.02 mL/min). Pilocarpine increased the flow above that observed with placebo (0.66 ± 0.19 vs. 0.15 ± 0.02 mL/min). Thus, pilocarpine re-establishes the flow of saliva in the state of tramadol-induced oral dryness.

Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial

1997 ◽  
Vol 27 (8) ◽  
pp. 860-867 ◽  
Author(s):  
V.A. VARNEY ◽  
J. EDWARDS ◽  
K. TABBAH ◽  
H. BREWSTER ◽  
G. MAVROLEON ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Specific Immunotherapy ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

A randomized double blind, placebo controlled trial of a Chinese herbal preparation (CH100) in chronic Hepatitis C

2001 ◽  
Vol 120 (5) ◽  
pp. A384-A384
Author(s):  
L MOLLISON ◽  
L TOTTEN ◽  
C HOVELL ◽  
K THAYNE ◽  
C CONNELLY ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Controlled Trial ◽  
Herbal Preparation ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Chinese Herbal
Sign in / Sign up

Export Citation Format

Share Document